You are here

Company Monitoring Page for Novartis

latest headlines for company on cafepharma

It's A Big Weekend For Biotech

Yahoo/Benzinga

Sat, 04/18/15 - 11:55 am

Tags:

biotech, Biogen, BIIB037, RG7800, PTC Therapeutics, Alnylam, CAR-T, Merck, Bristol-Myers Squibb, Novartis, Juno Therapeutics, Bellicum

Amgen motion to delay Neupogen biosimilar denied

Medical Marketing and Media

Fri, 04/17/15 - 08:44 am

Tags:

Amgen, Neupogen, biosimilars, Zarxio, Novartis, Sandoz

Novartis has fresh data to support newly acquired CCL drug Arzerra

Fierce Pharma

Wed, 04/15/15 - 10:30 am

Tags:

Novartis, Arzerra, chronic lymphocytic leukemia, GSK

Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO

Fierce Biotech

Thu, 04/9/15 - 10:01 am

Tags:

IPOs, Merus, JNJ, Novartis, Pfizer, immuno-oncology

The largest biopharma layoffs of 2014

Fierce Pharma

Tue, 04/7/15 - 11:10 am

Tags:

layoffs, Amgen, Novartis, Allergan, GSK, Boehringer Ingelheim, Actavis, AstraZeneca

10 Largest Companies by Market Cap in Pharmaceuticals

Motley Fool

Mon, 04/6/15 - 05:37 pm

Tags:

JNJ, Novartis, Pfizer, Merck, Sanofi, GSK, Bristol-Myers Squibb, AbbVie, AstraZeneca, Eli Lilly

Did Novartis try to sabotage Avastin ophthalmic trials?

BioPharma Dive

Mon, 04/6/15 - 10:54 am

Tags:

Novartis, Avastin, Roche, Lucentis

Glaxo's post-Novartis vax deal reorg could uproot hundreds of jobs

BioPharma Dive

Mon, 04/6/15 - 10:52 am

Tags:

GSK, Novartis, vaccines, layoffs

Juno and Novartis settle CAR-T patent fight with little fanfare

Fierce Biotech

Mon, 04/6/15 - 10:07 am

Tags:

Juno Therapeutics, Novartis, patents, CAR-T

BMJ: Novartis tried to 'scupper' trials to protect Lucentis from cheap Avastin

Fierce Pharma

Thu, 04/2/15 - 11:52 am

Tags:

Novartis, clinical trials, Roche, Avastin, Lucentis

Amgen loses another round in its battle to fend off a biosimilar rival

Marketwatch

Mon, 03/30/15 - 09:23 pm

Tags:

Amgen, biosimilars, Neupogen, Zarxio, Novartis

Glaxo finally strikes UK deal for Bexsero that eluded Novartis

BioPharma Dive

Mon, 03/30/15 - 10:59 am

Tags:

GSK, Novartis, Bexsero, UK

Novartis bulks up in immuno-oncology with a $750M Aduro deal

Fierce Biotech

Mon, 03/30/15 - 09:57 am

Tags:

Novartis, Aduro BioTech, immuno-oncology

11 promising drugs poised to be the next billion-dollar blockbusters

Yahoo/Business Insider

Sat, 03/28/15 - 10:26 am

Psoriasis data wars heat up at AAD with Novartis, Boehringer studies

Fierce Pharma Marketing

Thu, 03/26/15 - 07:38 am

Tags:

Novartis, psoriasis, Boehringer Ingelheim, Pfizer, Xeljanz, Cosentyx, JNJ, Stelara, BI-655066, Amgen, AstraZeneca, Merck, Eli Lilly

Amgen to appeal rejection of bid to block Novartis biosimilar drug

Yahoo/Reuters

Wed, 03/25/15 - 03:18 pm

Tags:

Amgen, Novartis, Neupogen, biosimilars, Zarxio

Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales

Fierce Pharma Marketing

Wed, 03/25/15 - 03:13 pm

Tags:

drug launches, Opdivo, Bristol-Myers Squibb, Praluent, Sanofi, Regeneron, LCZ696, Novartis

Novartis chief: Sometimes you have to kill your R&D darlings

Fierce Biotech

Wed, 03/25/15 - 09:02 am

Tags:

Novartis, Joe Jimenez, R&D

Why 2015 is the year of the biopharma blockbuster—with charts

BioPharma Dive

Tue, 03/24/15 - 10:29 am

Tags:

biotech, Opdivo, Praluent, LCZ696, Ibrance, Viekira Pak, evolocumab, Gardasil 9, Bristol-Myers Squibb, Regeneron, Sanofi, Novartis, Pfizer, Vertex Pharmaceuticals, Merck, Amgen, AbbVie, Astellas

Novartis, Lilly lead a $44M round for rare disease biotech Aeglea

Fierce Biotech

Tue, 03/24/15 - 10:22 am

Tags:

Novartis, Eli Lilly, Aeglea

Pages

last 30 twitter posts